{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-075435","form_type":"8-K","ticker":"BCYC","cik":"0001761612","company_name":"BICYCLE THERAPEUTICS PLC","filed_at":"2025-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.910680+00:00","generated_at":"2026-05-17T16:42:45.804766+00:00","sec_items":["2.02","5.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Bicycle Therapeutics Q2 net loss widens to $1.14/share; cuts workforce 30% to extend runway","bullets":["Net loss $79.0M ($1.14/share) vs $39.8M ($0.77) a year ago; R&D spend rose 77% to $71.0M.","Cash $721.5M at June 30, down from $879.5M at Dec 31; company expects runway through 2028 after cost realignment.","Workforce reduction of ~30% announced; Duravelo-5 trial paused while Duravelo-4 (NECTIN4-amplified NSCLC) enrolling.","Charles Swanton appointed to Board and Scientific Committee; new Research & Innovation Advisory Board formed.","Key catalyst: FDA meeting planned 4Q 2025 for zelenectide pevedotin accelerated approval pathway in mUC."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-075435","json":"https://secwatch.observer/filing/0001104659-25-075435.json","markdown":"https://secwatch.observer/filing/0001104659-25-075435.md","text":"https://secwatch.observer/filing/0001104659-25-075435.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1761612/000110465925075435/0001104659-25-075435-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1761612/000110465925075435/tm2522885d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T16:42:45.804766+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}